Abyssinia Biosciences Inc, a preclinical stage biotech company developing drugs and vaccines to treat and prevent Alzheimer's disease, announced on Thursday that it has signed a collaborative agreement with Cordance Medical, a preclinical stage medical technology company focused on improving patient outcomes in brain diseases through its NeuroAccess platform.

The two companies plan to explore focused ultrasound in diagnostic and therapeutic applications for Alzheimer's disease.

The collaboration will focus on early identification of toxic amyloid abnormalities in Alzheimer's disease by using Cordance Medical's ultrasound mediated SonoBiopsy technology. Cordance's SonoScript technology will be used to investigate how focused ultrasound can enhance the brain biodistribution of Abyssinia's antibodies.

Bhaskar Ramamurthy, Cordance CEO and co-founder, said: "Ultrasound guided drug delivery is an emerging method to improve the efficacy and safety of A-beta immunotherapy. In addition to its potential to obtain liquid biopsies from brain tissue in a non-invasive way, focused ultrasound should continue to be explored as potentially one of the safest methods of monoclonal antibody brain delivery and targeted delivery to disease-relevant brain areas."